CA Patent

CA3197371A1 — Oncolytic immunotherapy by tumor micro-environment remodeling

Assigned to Kalivir Immunotherapeutics Inc · Expires 2022-05-27 · 4y expired

What this patent protects

The disclosure relates to modified oncolytic viruses. The modified oncolytic viruses of the disclosure comprise modification in the viral genome encoding exogenous nucleic acids to enhance the oncolytic immunotherapy by remodeling the tumor microenvironment and with enhanced syst…

USPTO Abstract

The disclosure relates to modified oncolytic viruses. The modified oncolytic viruses of the disclosure comprise modification in the viral genome encoding exogenous nucleic acids to enhance the oncolytic immunotherapy by remodeling the tumor microenvironment and with enhanced systemic delivery. The disclosure further relates to compositions comprising the modified oncolytic viruses, kits containing the same, and methods of using the oncolytic viruses.

Drugs covered by this patent

Patent Metadata

Patent number
CA3197371A1
Jurisdiction
CA
Classification
—
Expires
2022-05-27
Drug substance claim
No
Drug product claim
No
Assignee
Kalivir Immunotherapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.